View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Bőr-, Nemikórtani és Bőronkológiai Klinika Budapest Mária u. 41. 1085
Open access

Az infliximab egy tumornekrózis-faktor-α-blokkoló rekombináns monoklonális antitest, amely hatékony terápiás lehetőséget biztosít psoriasisban és még számos immunmediált gyulladásos betegségben. Jól tolerálható és jelentősen javítja a beteg életminőségét. A szerzők célja az egyik lehetséges mellékhatás, a gyógyszer indukálta lupus erythematosus bemutatása egy eset kapcsán. A beteg psoriasisa kilenc éve jelentkezett béta-receptor-blokkoló gyógyszer szedése folyamán. A kezdetben alkalmazott lokális, majd szisztémás kezelés, illetve fényterápia ellenére tünetei súlyosbodtak, ezért a beteg biológiai terápia indítására szorult. A kezelés harmadik évében jelentkező általános panaszok kivizsgálásakor lupusszerű szindrómát diagnosztizáltak. A biológiai terápia elhagyása és alacsony dózisú szteroidkúra indítása után a beteg tünetei és kóros laboratóriumi paraméterei javulást mutattak. A szerzők kiemelik, hogy a biológiai terápia hatékony, de nem veszélytelen eljárás psoriasis kezelésében. Az esetlegesen fellépő mellékhatások csökkentése csak a betegek gondos követése mellett lehetséges. Bármilyen általános tünet alapos kivizsgálást igényel, mert hátterében esetenként a biológiai terápiával összefüggő súlyos mellékhatások vagy betegségek állhatnak. Orv. Hetil., 2013, 154, 590–598.

  • Chang, C., Gershwin, M. E.: Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf., 2011, 34, 357–374.

    Gershwin M. E. , 'Drug-induced lupus erythematosus: incidence, management and prevention ' (2011 ) 34 Drug Saf. : 357 -374.

    • Search Google Scholar
  • Marzano, A. V., Vezzoli, P., Crosti, C.: Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009, 18, 935–940.

    Crosti C. , 'Drug-induced lupus: an update on its dermatologic aspects ' (2009 ) 18 Lupus : 935 -940.

    • Search Google Scholar
  • Fry, L., Baker, B. S.: Triggering psoriasis: the role of infections and medications. Clin. Dermatol., 2007, 25, 606–615.

    Baker B. S. , 'Triggering psoriasis: the role of infections and medications ' (2007 ) 25 Clin. Dermatol. : 606 -615.

    • Search Google Scholar
  • Reich, K., Burden, A. D., Eaton, J. N., et al.: Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br. J. Dermatol., 2012, 166, 179–188.

    Eaton J. N. , 'Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials ' (2012 ) 166 Br. J. Dermatol. : 179 -188.

    • Search Google Scholar
  • Viguier, M., Pagès, C., Aubin, F., et al.: Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br. J. Dermatol., 2012, 167, 417–423.

    Aubin F. , 'Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study ' (2012 ) 167 Br. J. Dermatol. : 417 -423.

    • Search Google Scholar
  • Bagel, J., Lynde, C., Tyring, S., et al.: Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J. Am. Acad. Dermatol., 2012, 67, 86–92.

    Tyring S. , 'Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept ' (2012 ) 67 J. Am. Acad. Dermatol. : 86 -92.

    • Search Google Scholar
  • Atteno, M., Peluso, R., Costa, L., et al.: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin. Rheumatol., 2010, 29, 399–403.

    Costa L. , 'Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs ' (2010 ) 29 Clin. Rheumatol. : 399 -403.

    • Search Google Scholar
  • Barker, J., Hoffmann, M., Wozel, G., et al.: Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br. J. Dermatol., 2011, 165, 1109–1117.

    Wozel G. , 'Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) ' (2011 ) 165 Br. J. Dermatol. : 1109 -1117.

    • Search Google Scholar
  • Saurat, J. H., Stingl, G., Dubertret, L., et al.: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol., 2008, 158, 558–566.

    Dubertret L. , 'Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) ' (2008 ) 158 Br. J. Dermatol. : 558 -566.

    • Search Google Scholar
  • Saurat, J. H., Langley, R. G., Reich, K., et al.: Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br. J. Dermatol., 2011, 165, 399–406.

    Reich K. , 'Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study ' (2011 ) 165 Br. J. Dermatol. : 399 -406.

    • Search Google Scholar
  • Lin, V. W., Ringold, S., Devine, E. B.: Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch. Dermatol., 2012, 148, 1403–1410.

    Devine E. B. , 'Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis ' (2012 ) 148 Arch. Dermatol. : 1403 -1410.

    • Search Google Scholar
  • Reich, K., Signorovitch, J., Ramakrishnan, K., et al.: Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J. Am. Acad. Dermatol., 2010, 63, 1011–1018.

    Ramakrishnan K. , 'Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial ' (2010 ) 63 J. Am. Acad. Dermatol. : 1011 -1018.

    • Search Google Scholar
  • Brooklyn, T. N., Dunnill, M. G., Shetty, A., et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 2006, 55, 505–509.

    Shetty A. , 'Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial ' (2006 ) 55 Gut : 505 -509.

    • Search Google Scholar
  • Uthman, I. W., Touma, Z., Sayyad, J., et al.: Response of deep cutaneous vasculitis to infliximab. J. Am. Acad. Dermatol., 2005, 53, 353–354.

    Sayyad J. , 'Response of deep cutaneous vasculitis to infliximab ' (2005 ) 53 J. Am. Acad. Dermatol. : 353 -354.

    • Search Google Scholar
  • Jacobi, A., Antoni, C., Manger, B., et al.: Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol., 2005, 52 (3 Pt 1), 522–526.

    Manger B. , 'Infliximab in the treatment of moderate to severe atopic dermatitis ' (2005 ) 52 J. Am. Acad. Dermatol. : 522 -526.

    • Search Google Scholar
  • Sullivan, T. P., Welsh, E., Kerdel, F. A., et al.: Infliximab for hidradenitis suppurativa. Br. J. Dermatol., 2003, 149, 1046–1049.

    Kerdel F. A. , 'Infliximab for hidradenitis suppurativa ' (2003 ) 149 Br. J. Dermatol. : 1046 -1049.

    • Search Google Scholar
  • Bargagli, E., Galeazzi, M., Bellisai, F., et al.: Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration, 2008, 75, 346–349.

    Bellisai F. , 'Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension ' (2008 ) 75 Respiration : 346 -349.

    • Search Google Scholar
  • Pardo, J., Mercader, P., Mahiques, L., et al.: Infliximab in the management of severe pemphigus vulgaris. Br. J. Dermatol., 2005, 153, 222–223.

    Mahiques L. , 'Infliximab in the management of severe pemphigus vulgaris ' (2005 ) 153 Br. J. Dermatol. : 222 -223.

    • Search Google Scholar
  • Holló, P., Szakonyi, J., Kiss, D., et al.: Successful treatment of lichen planus with adalimumab. Acta Derm. Venereol., 2012, 92, 385–386.

    Kiss D. , 'Successful treatment of lichen planus with adalimumab ' (2012 ) 92 Acta Derm. Venereol. : 385 -386.

    • Search Google Scholar
  • Günther, C., Aringer, M., Lochno, M., et al.: TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. Acta Derm. Venereol., 2012, 92, 401–403.

    Lochno M. , 'TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus ' (2012 ) 92 Acta Derm. Venereol. : 401 -403.

    • Search Google Scholar
  • Chang, C., Gershwin, M. E.: Drugs and autoimmunity – a contemporary review and mechanistic approach. J. Autoimmun., 2010, 34, J266–J275.

    Gershwin M. E. , 'Drugs and autoimmunity – a contemporary review and mechanistic approach ' (2010 ) 34 J. Autoimmun. : J266 -J275.

    • Search Google Scholar
  • Vedove, C. D., Del Giglio, M., Schena, D., et al.: Drug-induced lupus erythematosus. Arch. Dermatol. Res., 2009, 301, 99–105.

    Schena D. , 'Drug-induced lupus erythematosus ' (2009 ) 301 Arch. Dermatol. Res. : 99 -105.

  • Atzeni, F., Sarzi-Puttini, P., Dell’Acqua, D., et al.: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther., 2006, 8, R3.

    Dell’Acqua D. , 'Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study ' (2006 ) 8 Arthritis Res. Ther. : R3 -.

    • Search Google Scholar
  • Poulalhon, N., Begon, E., Lebbé, C., et al.: A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br. J. Dermatol., 2007, 156, 329–336.

    Lebbé C. , 'A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity ' (2007 ) 156 Br. J. Dermatol. : 329 -336.

    • Search Google Scholar
  • Bacquet-Deschryver, H., Jouen, F., Quillard, M., et al.: Impact of three anti-TNF-alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J. Clin. Immunol., 2008, 28, 445–455.

    Quillard M. , 'Impact of three anti-TNF-alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients ' (2008 ) 28 J. Clin. Immunol. : 445 -455.

    • Search Google Scholar
  • Dalle Vedove, C., Simon, J. C., Girolomoni, G.: Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF-α agents. J. Dtsch. Dermatol. Ges., 2012, 10, 889–897.

    Girolomoni G. , 'Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF-α agents ' (2012 ) 10 J. Dtsch. Dermatol. Ges. : 889 -897.

    • Search Google Scholar
  • Atzeni, F., Turiel, M., Capsoni, F., et al.: Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci., 2005, 1051, 559–569.

    Capsoni F. , 'Autoimmunity and anti-TNF-alpha agents ' (2005 ) 1051 Ann. N. Y. Acad. Sci. : 559 -569.

    • Search Google Scholar
  • Zirwas, M. J., Kress, D. W., Deng, J. S.: The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus. Arch. Dermatol., 2004, 140, 494–495.

    Deng J. S. , 'The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus ' (2004 ) 140 Arch. Dermatol. : 494 -495.

    • Search Google Scholar
  • De Bandt, M., Sibilia, J., Le Loët, X., et al., Club Rhumatismes et Inflammation: Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther., 2005, 7, R545–R551.

    Loët X. , 'Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey ' (2005 ) 7 Arthritis Res. Ther. : R545 -R551.

    • Search Google Scholar
  • Subramanian, S., Yajnik, V., Sands, B. E.: Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm. Bowel Dis., 2011, 17, 99–104.

    Sands B. E. , 'Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent ' (2011 ) 17 Inflamm. Bowel Dis. : 99 -104.

    • Search Google Scholar
  • Williams, V. L., Cohen, P. R.: TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol., 2011, 50, 619–625.

    Cohen P. R. , 'TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists ' (2011 ) 50 Int. J. Dermatol. : 619 -625.

    • Search Google Scholar
  • Costa, M. F., Said, N. R., Zimmermann, B.: Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin. Arthritis Rheum., 2008, 37, 381–387.

    Zimmermann B. , 'Drug-induced lupus due to anti-tumor necrosis factor alpha agents ' (2008 ) 37 Semin. Arthritis Rheum. : 381 -387.

    • Search Google Scholar
  • Williams, E. L., Gadola, S., Edwards, C. J.: Anti-TNF-induced lupus. Rheumatology (Oxford), 2009, 48, 716–720.

    Edwards C. J. , 'Anti-TNF-induced lupus ' (2009 ) 48 Rheumatology (Oxford) : 716 -720.

  • Marzano, A. V., Vezzoli, P., Crosti, C.: Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009, 18, 935–940.

    Crosti C. , 'Drug-induced lupus: an update on its dermatologic aspects ' (2009 ) 18 Lupus : 935 -940.

    • Search Google Scholar
  • Antonov, D., Kazandjieva, J., Etugov, D., et al.: Drug-induced lupus erythematosus. Clin. Dermatol., 2004, 22, 157–166.

    Etugov D. , 'Drug-induced lupus erythematosus ' (2004 ) 22 Clin. Dermatol. : 157 -166.

  • Rubin, R. L.: Drug-induced lupus. Toxicology, 2005, 209, 135–147.

    Rubin R. L. , 'Drug-induced lupus ' (2005 ) 209 Toxicology : 135 -147.

  • Almoallim, H., Al-Ghamdi, Y., Almaghrabi, H., et al.: Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol. J., 2012, 6, 315–319.

    Almaghrabi H. , 'Anti-tumor necrosis factor-α induced systemic lupus erythematosus ' (2012 ) 6 Open Rheumatol. J. : 315 -319.

    • Search Google Scholar
  • Vasoo, S.: Drug-induced lupus: an update. Lupus, 2006, 15, 757–761.

    Vasoo S. , 'Drug-induced lupus: an update ' (2006 ) 15 Lupus : 757 -761.

  • Stokes, M. B., Foster, K., Markowitz, G. S., et al.: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol. Dial. Transplant., 2005, 20, 1400–1406.

    Markowitz G. S. , 'Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis ' (2005 ) 20 Nephrol. Dial. Transplant. : 1400 -1406.

    • Search Google Scholar
  • Chadha, T., Hernandez, J. E.: Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum., 2006, 55, 163–166.

    Hernandez J. E. , 'Infliximab-related lupus and associated valvulitis: a case report and review of the literature ' (2006 ) 55 Arthritis Rheum. : 163 -166.

    • Search Google Scholar
  • Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., et al.: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore), 2007, 86, 242–251.

    Muñoz S. , 'Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases ' (2007 ) 86 Medicine (Baltimore) : 242 -251.

    • Search Google Scholar
  • Wetter, D. A., Davis, M. D.: Lupus-like syndrome stributable to anti-tumor necrosis factor α therapy in 14 patient during an 8-year period at Mayo Clinic. Mayo Clin. Proc., 2009, 84, 979–984.

    Davis M. D. , 'Lupus-like syndrome stributable to anti-tumor necrosis factor α therapy in 14 patient during an 8-year period at Mayo Clinic ' (2009 ) 84 Mayo Clin. Proc. : 979 -984.

    • Search Google Scholar
  • Ye, C., Sholter, D., Martin, L., et al.: Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF) -induced lupus to another anti-TNF agent. J. Rheumatol., 2011, 38, 1216. Author reply 1217–1218.

    Martin L. , 'Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF) -induced lupus to another anti-TNF agent ' (2011 ) 38 J. Rheumatol. : 1216 -.

    • Search Google Scholar
  • Williams, V. L., Cohen, P. R.: TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol., 2011, 50, 619–625.

    Cohen P. R. , 'TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists ' (2011 ) 50 Int. J. Dermatol. : 619 -625.

    • Search Google Scholar
  • Puertas-Abreu, E., Polanco, E. R., Azocar, M., et al.: Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int. Arch. Med., 2012, 5, 7. doi: 10.1186/1755–7682-5-7

    Azocar M. , 'Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α ' (2012 ) 5 Int. Arch. Med. : 7 -.

    • Search Google Scholar
  • Sifuentes Giraldo, W. A, Ahijón Lana, M., García Villanueva, M. J., et al.: Chilblain lupus induced by TNF-α antagonists: a case report and literature review. Clin. Rheumatol., 2012, 31, 563–568.

    García Villanueva M. J. , 'Chilblain lupus induced by TNF-α antagonists: a case report and literature review ' (2012 ) 31 Clin. Rheumatol. : 563 -568.

    • Search Google Scholar
  • Pink, A. E., Fonia, A., Allen, M. H., et al.: Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br. J. Dermatol., 2010, 162, 780–785.

    Allen M. H. , 'Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study ' (2010 ) 162 Br. J. Dermatol. : 780 -785.

    • Search Google Scholar
  • Iwata, D., Namba, K., Mizuuchi, K., et al.: Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab. Graefes Arch. Clin. Exp. Ophthalmol., 2012, 250, 1081–1087.

    Mizuuchi K. , 'Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab ' (2012 ) 250 Graefes Arch. Clin. Exp. Ophthalmol. : 1081 -1087.

    • Search Google Scholar
  • Jókai, H., Szakonyi, J., Kontár, O., et al.: Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis. Exp. Dermatol., 2013, 22, 221–223.

    Kontár O. , 'Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis ' (2013 ) 22 Exp. Dermatol. : 221 -223.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 38 37 2
PDF Downloads 103 94 14